Gene transfer of CD40-ligand to dendritic cells stimulates interferon-γ production to induce growth arrest and apoptosis of tumor cells

Gene Therapy

Volumn 15, Issue 3, 2008, Pages 203-213

  Tomihara, K ^a   Kato, K ^a   Masuta, Y ^a   Nakamura, K ^a   Uchida, H ^a   Sasaki, K ^a   Tanaka, T ^a   Huang, J ^a   Hiratsuka, H ^a   Hamada, H ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CD40 LIGAND; DEATH RECEPTOR 5; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; INTERLEUKIN 12P70; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL BASED GENE THERAPY; CELL STIMULATION; COCULTURE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE TRANSFER; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR XENOGRAFT; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CD40 LIGAND; CELL LINE, TUMOR; DENDRITIC CELLS; GENE EXPRESSION; GENE THERAPY; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, NUDE; MODELS, ANIMAL; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SKIN NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

ADENOVIRIDAE;

EID: 38549143194     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3303056     Document Type: Article

References (47)

1. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricte 1 CTLs. Nature 1998; 392: 86-89.
2. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Mahszewski CR, Faliger NA. Monocyte-mediated tumoricidal Activity via the turpor necrosis factor-related cytokine, TRAIL. J Exp Med 1998; 189: 1343-1354.
3. Fanger NA, Maliszewski CR, Schooley K, Griffith TS. Human, dendzitic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 1999; 190: 1155-1164.
4. Vidalain PO, Azocar O, Yagita H, Rabourdin-combe C, Servet-Delpart C. Cytotoxic activity of human dendritic cells is differentiaidy regulated by double-stranded RNA and CD40 ligand. J Immunol 2001; 167: 3765-3772.
5. Chapoval AI, Tamada K, Chen L. In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. Blood 2000; 95: 2346-2351.
6. Caux. C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I et al. Activation of human dendritec cells through CD40 cross-hnking. J Exp Med 1994; 180: 1263-1272.
7. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284: 1835-1837.
8. Palucka K, Banchereau J. Linking innate and adaptive immunity. Nat Med 1999; 5: 868-870.
9. Puddu P, Fantuzzi L, Borghi P, Varano, B, Rainaldi G, Guillemard E et al. IL-12 induces IFN-gamma expression. and secretion in mouse peritoneal macrophages. J Immunol 1997; 159: 3490-3497.
10. Munder M, Mallo M, Eichmann, K, Modolell M. - Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation. J Exp Med 1998; 187: 2103-2108.
11. Ohteki T, Fukao T, Suzue K, Maki C, Ito M, Nakamura M et al. Interleukin 12-dependent interferon gamma production by CD8a1pha+ lymphoid dendritic cells. J Exp Med 19997 189: 1981-1986.
12. Fukao, T, Matsuda S, Koyasu S. Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-gamma production by dendritic cells. J Immunol 2000; 164: 64--71.
13. Pan G, O'rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J et al. The receptor for the cytotoxic hgand TRAIL. Science 1997; 276 111-113.
14. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N et al. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16: 5386-5397.
15. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS et al. p53-dependent and -independent regulation of the death receptor KILLER/ DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998; 58: 1593-1598.
16. Chinnaiyan AM, Prasad U, Shakar S, Hamstra DA, Shanaiah M, Chenevert TL et al. Combined effect of tumor necrosis factor-related apoptosis-inducing hgand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000; 97: 1754-01759.
17. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ et al. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000; 60: 847-853.
18. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16: 487-494.
19. Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 1995; 55: 3149-3157.
20. Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994; 91: 9461-9465.
21. Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LEA-1). Cell 1997; 51: 813-819.
22. Becker JC, Dummer R, Hartmann AA, Burg G, Schmidt RE. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol 1991; 147: 4398-4401.
23. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18: 89-95.
24. Romero JM, Jimenez P, Cabrera T, Cozar JM, Pedrinaci S, Tallada M et al. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer 2005; 113: 605-610.
25. Sedger LM, Shows DM, Blanton RA, Peschon JJ, Goodwin RG, Cosman D et al. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 1999; 163: 920-926.
26. Merchant MS, Yang X, Melchionda F, Romero M, Klein R, Thiele CJ et al Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res 2004; 64: 8349-8356.
27. Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: Involvement of TRAF3 as a common mediator. Oncogene 1996; 13: 2243-2254.
28. Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000; 20: 5503-5515.
29. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science 2002; 296: 1653-1655.
30. Choi EA, Lei H, Maron DJ, Wilson JM, Barsoum J, Fraker DL et al. Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. Cancer Res 2003; 63 5299-5307.
31. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833-2840.
32. Miyasaki T, Reed JC. A GTP-binding adapter proteiii couples TRAIL receptors to apoptosis-inducing proteins. Nat Immunol 2001; 2 493-500.
33. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001; 276: 10767-10774.
34. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001; 20: 6073-6083.
35. Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C et al. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance. J Biol Chem 2001; 276: 38361-38369.
36. Martelli, AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 2003; 17: 1794-1805.
37. Kikuchi T, Moore MA, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 2000; 96: 91-99.
38. Kikuchi T, Miyazawa N, Moore MA, Crystal RG. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res 2000; 60: 6391-6395.
39. Hemmings BA. Akt signaling: Linking membrane events to life and death decisions. Science 1997; 275: 628-630.
40. Kennedy SG, Kandel ES, Cross TK, Hay N. Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 1998; 19: 5800-5810.
41. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001; 193: 661-670.
42. Miyazaki A, Sato N, Takahashi S, Sasaki A, Kohama G, Yamaguchi A et al. Cytotoxicity of histocompatibility leukocyte antigen-DR8-restricted CD4 killer T cells against human autologous squamous cell carcinoma. Jpn J Cancer Res 1997; 88: 191-197.
43. Nakamura T, Sato K, Hamada H. Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors. Hum Gene Ther 2002; 13: 613-626.
44. Yoshida Y, Sadata A, Zhang W, Saito K, Shinoura N, Hamada H. Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. Hum Gene Ther 1998; 9: 2503-2515.
45. Kanegae Y, Lee G, Sato Y, Tanaka M, Nakai M, Sakaki T et al. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res 1995; 23: 3816-3821.
46. Nyberg-Hoffman C, Shabram P, Li W, Giroux D, Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med 1997; 3: 808-811.
47. Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y et al. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 2004; 10: 162-171.